

PALIGENT INC
Form 10-Q
November 14, 2005

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2005

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 0-21134

Paligent Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

04-2893483
(I.R.S. Employer
Identification No.)

10 East 53rd Street, New York, New York
(Address of principal executive offices)

10022
(zip code)

(212) 755-5461
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES NO

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

YES NO

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES NO

Edgar Filing: PALIGENT INC - Form 10-Q

The number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

| Class | Outstanding as of November 4, 2005 |
|--------------------------------|------------------------------------|
| Common Stock, \$0.01 par value | 32,490,948 |

PALIGENT INC.

INDEX

PART I.

FINANCIAL INFORMATION

Item 1.

Financial Statements

Condensed Consolidated Balance Sheets September 30, 2005 (unaudited) and December 31, 2004

Condensed Consolidated Statements of Operations (unaudited) Three and nine months ended September 30, 2005 and 2004

Condensed Consolidated Statements of Cash Flows (unaudited) Nine months ended September 30, 2005 and 2004

Notes to Condensed Consolidated Financial Statements (unaudited)

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 3.

Quantitative and Qualitative Disclosure About Market Risk

Item 4.

Controls and Procedures

PART II.

OTHER INFORMATION

Item 6.

Exhibits

SIGNATURES

EXHIBIT INDEX

PALIGENT INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

| | September 30, 2005 (unaudited) | December 31, 2004 |
|---|-----------------------------------|-------------------|
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 15,087 | \$ 21,388 |
| Note receivable | 75,000 | |
| Current portion of subtenant receivable, including accrued interest | | 30,000 |
| Prepaid expenses and other current assets | 10,882 | |
| Total current assets | 100,969 | 51,388 |
| Property and equipment, net | | 941 |
| Total assets | \$ 100,969 | \$ 52,329 |
| LIABILITIES AND STOCKHOLDERS DEFICIT | | |
| Current liabilities: | | |
| Accounts payable and accrued expenses | \$ 59,539 | \$ 54,639 |
| Accrued professional services | 26,100 | 21,900 |
| Due to related party | 441,713 | 203,290 |
| Total current liabilities | 527,352 | 279,829 |
| Stockholders' deficit: | | |
| Common stock, \$.01 par value; 75,000,000 shares authorized; 32,490,948 shares issued and outstanding at September 30, 2005 and December 31, 2004 | 324,910 | 324,910 |
| Additional paid-in capital | 154,634,974 | 154,634,974 |
| Accumulated deficit | (155,386,267) | (155,187,384) |
| Total stockholders' deficit | (426,383) | (227,500) |
| Total liabilities and stockholders' deficit | \$ 100,969 | \$ 52,329 |

The accompanying notes are an integral part of the condensed consolidated financial statements.

PALIGENT INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

| | Three months ended September 30, | | Nine months ended September 30, | |
|--|----------------------------------|------------|---------------------------------|--------------|
| | 2005 | 2004 | 2005 | 2004 |
| Revenue: | | | | |
| Interest income | \$ | \$ | \$ | \$ 2,250 |
| Costs and expenses: | | | | |
| General and administrative | | 122,667 | 214,137 | 340,133 |
| | | | | 537,882 |
| Loss from operations | | (122,667) | (214,137) | (340,133) |
| | | | | (535,632) |
| Other income | | | 500,000 | 141,250 |
| | | | | 500,000 |
| Net (loss) income | \$ | (122,667) | \$ 285,863 | \$ (198,883) |
| | | | | \$ (35,632) |
| Basic and diluted net (loss) income per common share | \$ | (0.00) | \$ 0.01 | \$ (0.01) |
| | | | | \$ (0.00) |
| Weighted average number of common shares outstanding Basic and diluted | | 32,490,948 | 32,490,948 | 32,490,948 |
| | | | | 32,490,948 |

The accompanying notes are an integral part of the condensed consolidated financial statements.

PALIGENT INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

| | Nine months ended September 30, | |
|---|---------------------------------|-------------|
| | 2005 | 2004 |
| Cash flows from operating activities: | | |
| Net loss | \$ (198,883) | \$ (35,632) |
| Adjustments to reconcile net loss to net cash used in operating activities: | | |
| Depreciation and amortization | 941 | 1,404 |
| Write-off of security deposits | | 9,543 |
| Write-down of accrued rent | | (81,185) |
| Deferred rent | | (22,262) |
| Reserve for subtenant receivable | | 77,250 |
| Changes in operating assets and liabilities: | | |
| Note receivable | (75,000) | |
| Prepaid expenses and other current assets | (10,882) | (29,996) |
| Subtenant receivable | 30,000 | 50,000 |
| Accounts payable and accrued expenses | 9,100 | (107,689) |
| Interest payable to related party | 18,423 | (1,189) |
| Accrued rent | | 114,600 |
| Net cash used in operating activities | (226,301) | (25,156) |
| Cash flows from investing activities: | | |
| Proceeds from sale of assets | | 10,000 |
| Net cash provided by investing activities | | 10,000 |
| Cash flows from financing activities: | | |
| Proceeds from related party loan | 220,000 | 405,000 |
| Repayment of related party loan | | (375,000) |
| Principal payments on capital lease obligations | | (10,000) |
| Net cash provided by financing activities | 220,000 | 20,000 |
| Net (decrease) increase in cash and cash equivalents | (6,301) | 4,844 |
| Cash and cash equivalents at beginning of period | 21,388 | 41,321 |
| Cash and cash equivalents at end of period | \$ 15,087 | \$ 46,165 |

The accompanying notes are an integral part of the condensed consolidated financial statements.

PALIGENT INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

NOTE 1 BASIS OF PRESENTATION

Interim Financial Statements

Edgar Filing: PALIGENT INC - Form 10-Q

The condensed consolidated financial statements included herein have been prepared by Paligent Inc. (Paligent or the Company) pursuant to the rules and regulations of the United States Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring accruals) necessary for a fair presentation of the financial position of the Company at September 30, 2005 and the results of its operations and its cash flows for the interim periods ended September 30, 2005 and 2004. The condensed consolidated balance sheet as of December 31, 2004 was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting standards for interim financial statements and should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company s Form 10-K for the year ended December 31, 2004. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the fiscal year or any other interim period.

The accompanying consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the ordinary course of business. The Company has incurred losses from operations since inception, has working capital and stockholders deficits and has limited cash to fund operations in 2005. The Company is presently relying on borrowings from its principal stockholder to fund continuing operations. The principal stockholder has made no commitment to continue to make loans to the Company.

While the Company evaluates strategic alternatives, including potential business investments and related financing, the Company s rate of spending could vary from its current estimate. No assurance can be given that the Company will be able to complete a business investment or that such financing will be available to the Company. If the Company is unable to generate significant revenue from acquired operations, obtain financing from its principal stockholder or secure sufficient financing for operations resulting from acquisition or merger, the Company will experience a cash shortage in 2005, the effect of which could result in the discontinuance of operations. If additional funds are raised by issuing equity securities, further dilution to existing stockholders will result and future investors may be granted rights superior to those of existing stockholders.

These circumstances raise substantial doubt about the Company s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Reclassification

Certain prior period amounts have been reclassified to conform to the current period presentation.

NOTE 2 BASIC AND DILUTED NET INCOME (LOSS) PER SHARE

Basic earnings per share (EPS) excludes dilution and is computed by dividing income (loss) applicable to common stockholders by the weighted average number of common shares outstanding for the period.

Diluted EPS is based upon the weighted average number of common shares outstanding during the period plus the additional weighted average common equivalent shares during the period. Common equivalent shares result from the assumed exercises of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding shares of common stock (the treasury stock method). Common equivalent shares are not included in the per share calculations where the effect of their inclusion would be anti-dilutive. Inherently, stock options and warrants are deemed to be anti-dilutive when the average market price of the common stock during the period exceeds the exercise price of the stock options or warrants.

For the three and nine months ended September 30, 2005 and 2004, the Company had stock options and warrants outstanding that were anti-dilutive. These securities could potentially dilute basic EPS in the future but were not included in the computation of diluted EPS for the periods presented because to do so would have been anti-dilutive. Consequently, there were no differences between basic and diluted EPS for these periods.

NOTE 3 SIGNIFICANT EVENT

In February 2005, the Company's subsidiary, Procept, Inc. (Procept), and the United States Public Health Service (PHS), represented by the National Institutes of Health, executed a third amendment (the Third Amendment) to the Exclusive Patent License Agreement (the License Agreement). The License Agreement affirmed and acknowledged Procept's worldwide patent rights to O6-Benzylguanine and acknowledges Procept's sublicensing of such rights to AOI Pharmaceuticals Inc. (AOI). The Third Amendment revised the provision for payment of an additional royalty to PHS upon the occurrence of an assignment by Procept of the License Agreement, decreasing such additional royalty to \$17,500 from \$20,000.

Subsequently, in March 2005, pursuant to an agreement by and between Procept, Keryx Biopharmaceuticals, Inc., the parent of AOI (Keryx) and PHS (the Assignment Agreement), Procept assigned all of its rights, interests and obligations under the License Agreement to Keryx; in exchange, Keryx agreed to pay Procept a total of \$158,750, in two installments. The first installment of \$83,750 was paid on March 30, 2005. The second installment of \$75,000 is payable on December 31, 2005 and is evidenced by a promissory note from Keryx payable to Procept, which bears no interest until after the maturity date. In connection with the Assignment Agreement, Procept paid to PHS the additional royalty of \$17,500, as provided for under the License Agreement, as amended in February 2005.

NOTE 4 SUBTENANT RECEIVABLE

On December 31, 2003, the Company executed a Surrender Agreement and Promissory Note with its former subtenant (the Subtenant) pursuant to which the Company received cash and a promissory note in exchange for the termination of a sublease. The Promissory Note, in the face amount of \$75,000, bore interest at the rate of 6% per annum and was to be payable in three installments of \$25,000, plus accrued interest, on June 30, 2004, December 31, 2004 and June 30, 2005. The cash portion of the settlement, in the amount of \$50,000, was received by the Company in January 2004. The Company did not receive from the Subtenant the installment payment that was due on June 30, 2004. On September 14, 2004, the Company filed an action in the Supreme Court of the State of New York, New York County, alleging that the Subtenant had defaulted on its obligations under the Promissory Note dated December 31, 2003 and, accordingly, discontinued accruing interest income as of June 30, 2004. In February 2005, the Company and the Subtenant reached a settlement of the Company's claim pursuant to which the Company received a one-time payment of \$30,000 in exchange for withdrawing its action.

NOTE 5 RELATED PARTIES

On October 8, 2003, in anticipation of completing a business combination with Digital Products of Delaware, Inc. (Digital) or another entity, the Company executed a promissory note (the Promissory Note) with Richard J. Kurtz, the principal stockholder of the Company and of Digital. Under the Promissory Note, the Company received, and expects to continue to receive, loans that will enable it to meet its anticipated cash operating needs. The Promissory Note bears interest at 8% per annum and contemplated repayment upon the occurrence of the earlier of (i) the first anniversary of the making of the first loan; and (ii) the first funding of debt and/or equity capital subsequent to the completion of the proposed business combination between the Company and Digital that results in aggregate net proceeds to the Company of not less than \$1 million. As the first anniversary of the Promissory Note has occurred, the amount due under the Promissory Note is payable on demand. During the nine months ended September 30, 2005, Mr. Kurtz loaned the Company an aggregate of \$220,000 to fund its continuing operations, increasing the principal balance due under the Promissory Note to \$420,000 at September 30, 2005.

NOTE 6 STOCK-BASED COMPENSATION

The Company complies with Statement of Financial Accounting Standards No. (FAS) 148, Accounting for Stock-Based Compensation - Transition and Disclosure, an Amendment of FAS 123. This statement provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, FAS 148 amends the disclosure requirements of FAS 123 to require more prominent and more frequent disclosures in financial statements about the effects of stock-based compensation.

The Company applies Accounting Principles Board Opinion No. (APB) 25, Accounting for Stock Issued to Employees, and related interpretations, in accounting for its stock-based compensation plans. Accordingly, no compensation cost has been recognized for its stock option plan. Had compensation cost for the Company's stock-based compensation plan been determined based on the fair value at the grant dates for awards under those plans consistent with FAS 123, the Company's net (loss) income and net (loss) income per share would have been adjusted to the pro forma amounts indicated below:

| | Three months ended September 30, | | Nine months ended September 30, | |
|--|----------------------------------|------------|---------------------------------|-------------|
| | 2005 | 2004 | 2005 | 2004 |
| Net (loss) income as reported | \$ (122,667) | \$ 285,863 | \$ (198,883) | \$ (35,632) |
| Adjustment to net (loss) income for pro forma stock-based compensation expense | | | | (27,089) |
| Net (loss) income pro forma | \$ (122,667) | \$ 285,863 | \$ (198,883) | \$ (62,721) |
| Basic and diluted net (loss) income per common share as reported | \$ (0.00) | \$ 0.01 | \$ (0.01) | \$ (0.00) |
| Basic and diluted net (loss) income per common share pro forma | \$ (0.00) | \$ 0.01 | \$ (0.01) | \$ (0.00) |

In December 2004, the Financial Accounting Standards Board issued FAS 123R, Share-Based Payment. FAS 123R is a revision of FAS 123, Accounting for Stock Based Compensation, and supersedes APB 25. Among other items, FAS 123R eliminates the use of APB 25 and the intrinsic value method of accounting, and requires companies to recognize the cost of employee services received in exchange for awards of equity instruments in the financial statements, based on the grant date fair value of those awards. The effective date of FAS 123R for the Company is January 1, 2006. FAS 123R permits companies to adopt its requirements using either a modified prospective method, or a

modified retrospective method. Under the modified prospective method, compensation cost is recognized in the financial statements beginning with the effective date, based on the requirements of FAS 123R for all share-based payments granted after that date, and based on the requirements of FAS 123 for all unvested awards granted prior to the effective date of FAS 123R. Under the modified retrospective method, the requirements are the same as under the modified prospective method, but also permits entities to restate financial statements of previous periods, either for all prior periods presented or to the beginning of the fiscal year in which the statement is adopted, based on previous pro forma disclosures made in accordance with FAS 123. The Company has not yet determined which of the methods it will use upon adoption.

The Company currently utilizes the Black-Scholes option pricing model to measure the fair value of stock options granted to employees. While FAS 123R permits entities to continue to use such a model, it also permits the use of a lattice model. The Company expects to continue using the Black-Scholes option pricing model upon adoption of FAS 123R to measure the fair value of stock options.

The adoption of this statement will have the effect of reducing net income and income per share as compared to what would be reported under the current requirements. These future amounts cannot be precisely estimated because they depend on, among other things, the number of options issued in the future, and accordingly, the Company has not determined the impact of adoption of this statement on its results of operations.

FAS 123R also requires that the benefits associated with the tax deductions in excess of recognized compensation cost be reported as a financing cash flow, rather than as an operating cash flow as required under current literature. This requirement will reduce net operating cash flows and increase net financing cash flows in periods after the effective date. These future amounts cannot be estimated, because they depend on, among other things, when employees exercise stock options.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Note Regarding Forward-Looking Statements

Statements in this Form 10-Q that are not statements or descriptions of historical facts are forward-looking statements under Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and are subject to numerous risks and uncertainties. These forward-looking statements can generally be identified by the use of such terms as anticipate, believe, continue, expect, may, should, or similar variations or the negative thereof. These forward looking statements involve risks and uncertainties, many of which are out of the Company's control and which may affect its future business plans. Factors that may affect the Company's future business plans include: (i) its ability to identify, complete and integrate an acquisition of an operating business; (ii) the viability of the Company's business strategy in connection with an acquisition and its ability to implement such strategy; and (iii) its ability to secure financing for its current costs and potential future operations. Such statements reflect the current view of the Company with respect to future events and are subject to certain risks, uncertainties and assumptions. In addition, the Company's business, operations and financial condition are subject to the risks, uncertainties and assumptions that are described in the Company's reports and statements filed from time to time with the Securities and Exchange Commission. Should one or more of those risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those discussed herein. The descriptions of the risks, uncertainties and assumptions to which the Company's business, operations and financial condition are subject are as of the date of this report. The Company assumes no obligation to update any such forward-looking statements.

Overview

Since 2001, Paligent Inc., together with its subsidiaries (collectively, the Company), has been engaged in seeking business opportunities to maximize value for its stockholders. The Company has evaluated various strategic alternatives, including acquisitions of new operating businesses and technologies as well as potential merger opportunities.

From its inception in 1985 through 1999, the Company operated as a biotechnology company engaged in the development and commercialization of novel drugs with a product portfolio focused on infectious diseases and oncology. During 1999, the Company's principal efforts were devoted to drug development and human clinical trials focusing on two biotechnology compounds, PRO 2000 Gel and O6-Benzylguanine (O6-BG). During fiscal 2000, the Company closed its research facilities and out-licensed PRO 2000 Gel and O6-BG. In September 2004, the Company transferred all of its rights, title and interest in PRO 2000 Gel pursuant to an option duly exercised by its sublicensee and in March 2005, the Company assigned all of its rights, interests and obligations in O6-BG to an affiliate of its sublicensee.

Results of Operations

From inception through September 30, 2005, the Company has generated no revenues from product sales or services and has not been profitable. As the Company evaluates various strategic alternatives in its quest for new growth areas that will maximize value to existing stockholders, the Company expects to incur additional losses.

Three and nine months ended September 30, 2005 as compared to the three and nine months ended September 30, 2004

Edgar Filing: PALIGENT INC - Form 10-Q

During the three months ended September 30, 2005, the Company reported a net loss of \$123,000, or \$0.00 per share, as compared to net income of \$286,000, or \$0.01 per share, in the comparable period in 2004. For the nine months ended September 30, 2005, the Company reported a net loss of \$199,000, or \$0.01 per share, as compared to a net loss of \$36,000, or \$0.00 per share, for the similar period in 2004.

The Company's total revenue, which is derived from interest income, was \$0 for the three and nine month periods ended September 30, 2005, as compared to \$0 and \$2,250, respectively, for the comparable three and nine month periods in 2004. Interest income in 2004 was attributable to the accrual of interest earnings on the subtenant note receivable.

The Company's total operating expenses, consisting of general and administrative costs, were \$123,000 and \$340,000, respectively, for the three and nine month periods ended September 30, 2005 as compared to \$214,000 and \$538,000, respectively, for the comparable periods in 2004. General and administrative costs for the three months ended September 30, 2004 included a reserve recorded against the subtenant receivable of \$77,000 (Reserve). Excluding the Reserve, general and administrative costs for the three month period ended September 30, 2004 were \$137,000, resulting in a net decrease of \$14,000 during the comparable three month period in 2005. For the nine months ended September 30, 2004, general and administrative costs includes the Reserve and a charge of \$51,000 relating to the fair value of costs that were expected to be incurred under the Company's former office lease (Lease End Costs). Excluding the charges for the Reserve and Lease End Costs, general and administrative costs were \$410,000 for the nine month period ended September 30, 2004, resulting in a net decrease of \$70,000 during the comparable nine month period in 2005. The decreases of \$14,000 and \$70,000 for the comparable three and nine month periods ended September 30, 2005 and 2004, respectively, are principally attributable to reductions in professional fees and insurance premiums.

During the nine months ended September 30, 2005, the Company assigned all of its rights, interest and obligations in O6-BG to its sublicensee for the contract amount of \$158,750. In connection with the assignment, the Company paid a royalty in the amount of \$17,500 to the United States Public Health Service. The net amount of this transaction is reflected as other income in the nine month period ended September 30, 2005. During the three and nine months ended September 30, 2004, the Company received proceeds of \$500,000 in connection with the exercise of an option by its sublicensee, upon which exercise, its sublicensee acquired all of the Company's rights, title and interest to PRO 2000 Gel. This transaction was recorded as other income for the three and nine month periods ended September 30, 2004.

Liquidity and Capital Resources

Edgar Filing: PALIGENT INC - Form 10-Q

At September 30, 2005, the Company's aggregate cash and cash equivalents were \$15,000, a net decrease of \$6,000 from the end of the prior year. Cash receipts during the nine months ended September 30, 2005 include net receipts of \$66,000 under the O6-BG assignment agreement, related party loans of \$220,000 and \$30,000 from the settlement of the subtenant receivable, offset by cash payments aggregating \$322,000 for operating activities.

The Company has incurred losses since inception, has working capital and stockholders' deficits and has limited cash to fund its operations. The Company is presently relying on borrowings from its principal stockholder to fund continuing operations. While the Company pursues strategic alternatives, including potential business combinations and related financing, the Company expects to finance its continuing operations through further borrowings from its principal stockholder. The stockholder has made no

commitment to continue to make loans to the Company. No assurance can be given that the Company will be able to complete a business combination or that such financing from its principal stockholder will continue to be available to the Company. If the Company is unable to generate significant revenue from acquired operations, obtain financing from its principal stockholder or secure sufficient financing for operations resulting from acquisition or merger, the Company will experience a cash shortage, the effect of which could result in the discontinuance of operations. If additional funds are raised by issuing equity securities, further dilution to existing stockholders will result and future investors may be granted rights superior to those of existing stockholders.

These circumstances raise substantial doubt about the Company's ability to continue as a going concern.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

In January 1997, the Securities and Exchange Commission issued Financial Reporting Release 48 (FRR 48), Disclosure of Accounting Policies for Derivative Financial Instruments and Derivative Commodity Instruments, and Disclosure of Quantitative and Qualitative Information About Market Risk Inherent in Derivative Financial Instruments, Other Financial Instruments and Derivative Commodity Instruments. FRR 48 required disclosure of qualitative and quantitative information about market risk inherent in derivative financial instruments, other financial instruments, and derivative commodity instruments beyond those already required under generally accepted accounting principles. The Company is not a party to any of the instruments discussed in FRR 48 and considers its market risk to be minimal.

Item 4. Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was performed under the supervision of the Company's Chief Executive Officer and Principal Financial Officer, of the effectiveness of the Company's disclosure controls and procedures. Based on that evaluation, the Company's Chief Executive Officer and Principal Financial Officer concluded that the Company's disclosure controls and procedures were effective as of the end of the period covered by this report. In addition, there were no changes in the Company's internal control over financial reporting during the quarter ended September 30, 2005 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION

Item 6. Exhibits.

31.1 Certification of Chief Executive Officer and Principal Financial Officer
Required by Rule 13a-14(a) or
Rule 15d-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Filed herewith.

32.1 Certification of Chief Executive Officer and Principal Financial Officer
Pursuant to 18 U.S.C. Section 1350, as
Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PALIGENT INC.
(Registrant)

Date: November 10, 2005

by: /s/ Salvatore A. Bucci
Salvatore A. Bucci
President and Chief Executive Officer

EXHIBIT INDEX

- 31.1 Certification of Chief Executive Officer and Principal Financial Officer Required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certification of Chief Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.